Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Operating Income of -$125.70 million for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$125.70M | +8.0% |
| 2024 | -$136.70M | -15.5% |
| 2023 | -$118.38M | -5.6% |
| 2022 | -$112.09M | -21.4% |
| 2021 | -$92.31M | -82.8% |
| 2020 | -$50.51M | -75.2% |
| 2019 | -$28.83M | -9.5% |
| 2018 | -$26.32M | -23.6% |
| 2017 | -$21.29M | +45.4% |
| 2016 | -$38.97M | +19.1% |
| 2015 | -$48.16M | -74.1% |
| 2014 | -$27.66M | -154.0% |
| 2013 | -$10.89M | -63.4% |
| 2012 | -$6.66M | -97.2% |
| 2011 | -$3.38M | -75.2% |
| 2010 | -$1.93M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$33.07M | -112.6% | -16.9% |
| June 30, 2025 | -$28.30M | +63.4% | -76.3% |
| March 31, 2025 | -$16.05M | +24.8% | -3.2% |
| September 30, 2024 | -$15.55M | +44.7% | +79.9% |
| June 30, 2024 | -$77.32M | -166.6% | -262.1% |
| March 31, 2024 | -$21.35M | +37.0% | +24.1% |
| September 30, 2023 | -$28.15M | +4.9% | +2.9% |
| June 30, 2023 | -$29.00M | -24.3% | +14.5% |
- Tonix Pharmaceuticals Holding Corp. showed an increase of +8.0% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Tonix Pharmaceuticals Holding Corp.’s operating income has declined by 6417.5% (from -$1.93 million to -$125.70 million).
- The most recent figure is from Tonix Pharmaceuticals Holding Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: